Genetically determined Alzheimer's disease research advances: The Down Syndrome & Autosomal Dominant Alzheimer's Disease 2024 Conference.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Falgàs Neus, Maure-Blesa Lucia, Ances Beau, Flores-Aguilar Lisi, Hartley Sigan, Hassenstab Jason, Iulita M Florencia, Janicki Matthew, Koenig Katherine, Lao Patrick, Levin Johannes, McDade Eric, Meijer Laurent, Rafii Michael S, Snyder Heather M, Sánchez-Valle Raquel, Fortea Juan, DSAD‐ADAD conference group, Arriola Infante Jose, Balasa Mirea, Barroeta Isabel, Barthelemy R Nicolas, Bejanin Alexandre, Benejam Bessy, Bosch Beatriz, Bradshaw Angela, Carmona-Iragui Maria, Cohen Ann, Comas Albertí Aina, Csincsik Lajos, Cuello A Claudio, Del Hoyo Soriano Laura, Dijkstra Janna, Edwards Natalie, Giménez Sandra, Gonzalez-Ortiz Fernando, Gordon Brian, Gutiérrez Fernández Sara, Handen Benjamin, Jacob Charlotte, Johnson Erik, Johansson Charlotte, Lladó Albert, Lleó Alberto, Morabito Samuel, Morcillo-Nieto Alejandra O, Montoliu-Gaya Laia, Okafor Michael, Pérez-Millan Agnes, Potier Marie Claude, Ringman John, Rodríguez-Baz Íñigo, Rubenstein Eric, Ryan Natalie S, Strydom André, Vaqué-Alcázar Lidia, Vermunt Lisa, Videla Toro Laura, Zaman Shahid
Аннотация
METHODS: This article provides a synthesis review of the conference proceedings, summarizing key discussions on biomarkers, natural history models, clinical trials, and ethical considerations in anti-amyloid therapies.
RESULTS: A total of 211 attendees from 16 countries joined the meeting. Global researchers presented on disease mechanisms, therapeutic developments, and patient care strategies. Discussions focused on challenges and opportunities unique to DSAD and ADAD. Experts emphasized the urgent need for tailored clinical trials for ADAD and DSAD and debated the safety and efficacy of anti-amyloid treatments. Ethical considerations highlighted equitable access to therapies and the crucial role of patient and caregiver involvement.
DISCUSSION: The conference highlighted the importance of inclusive research and collaboration across the genetic forms of AD.
HIGHLIGHTS: Biomarker research and natural history models developed in Down syndrome-associated Alzheimer's disease (DSAD) and autosomal dominant Alzheimer's disease (ADAD) enable the prediction of disease progression not only for DSAD and ADAD, but also for sporadic Alzheimer's disease (AD). -Collaboration and knowledge exchange among researchers across these genetic forms of AD will accelerate our understanding of the pathophysiology and advance preventive trials in DSAD and ADAD. -Tailored clinical trials for DSAD are urgently needed to address specific safety and efficacy concerns. -Inclusive research practices are crucial for advancing treatments and understanding of DSAD and ADAD.